Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA.
Buprenorphine
naloxone
opioid substitution treatment
opioid-related disorders
pharmacists
pharmacy
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
28
09
2020
received:
21
07
2020
accepted:
27
10
2020
pubmed:
4
11
2020
medline:
24
9
2021
entrez:
3
11
2020
Statut:
ppublish
Résumé
Patients with opioid use disorder (OUD) must be able to obtain prescribed buprenorphine/naloxone films (BUP/NX) and naloxone nasal spray (NNS) from a pharmacy promptly to reduce risk for a recurrence of use and subsequent morbidity and mortality. Telephone audits have identified concerning gaps in availability of NNS within US pharmacies, but the availability of BUP/NX has not been rigorously evaluated. This study estimated the availability of BUP/NX and NNS in the US state of Texas and compared availability by pharmacy type and metropolitan status. A cross-sectional telephone audit with a secret shopper approach conducted from 18 May 2020 to 7 June 2020. Setting and Participants A random sample of 800 of 5078 (16%) community pharmacies licensed with the Texas State Board of Pharmacy. Primary outcomes included availability of a 1-week supply of generic BUP/NX 8/2 mg films and a single unit of NNS 4 mg, overall and by pharmacy type. Secondary outcomes included willingness and estimated time-frame to order BUP/NX if unavailable. Data from 704 pharmacies (471 chain, 233 independent) were included for analyses. Of these, 34.1% of pharmacies (45.0% of chains versus 12.0% of independents, P < 0.0001) were willing and able to dispense a 1-week supply of generic BUP/NX and a single unit of NNS. BUP/NX alone was available in 42.2% of pharmacies (52.4% of chains versus 21.5% of independents, P < 0.0001). NNS alone was available in 60.1% of pharmacies (77.9% of chains versus 24.0% of independents, P < 0.0001). Of the 397 pharmacies with generic BUP/NX unavailable, 62.2% of pharmacies (73.9% of chains versus 48.0% of independents, P < 0.0001) indicated willingness to order. Most pharmacies in Texas do not appear to be willing and able to dispense prescribed buprenorphine/naloxone films and naloxone nasal spray to patients with opioid use disorder in a timely manner. Deficiencies in availability are markedly more pronounced in independent pharmacies compared with chain pharmacies.
Sections du résumé
BACKGROUND AND AIMS
Patients with opioid use disorder (OUD) must be able to obtain prescribed buprenorphine/naloxone films (BUP/NX) and naloxone nasal spray (NNS) from a pharmacy promptly to reduce risk for a recurrence of use and subsequent morbidity and mortality. Telephone audits have identified concerning gaps in availability of NNS within US pharmacies, but the availability of BUP/NX has not been rigorously evaluated. This study estimated the availability of BUP/NX and NNS in the US state of Texas and compared availability by pharmacy type and metropolitan status.
DESIGN
A cross-sectional telephone audit with a secret shopper approach conducted from 18 May 2020 to 7 June 2020. Setting and Participants A random sample of 800 of 5078 (16%) community pharmacies licensed with the Texas State Board of Pharmacy.
MEASUREMENTS
Primary outcomes included availability of a 1-week supply of generic BUP/NX 8/2 mg films and a single unit of NNS 4 mg, overall and by pharmacy type. Secondary outcomes included willingness and estimated time-frame to order BUP/NX if unavailable.
FINDINGS
Data from 704 pharmacies (471 chain, 233 independent) were included for analyses. Of these, 34.1% of pharmacies (45.0% of chains versus 12.0% of independents, P < 0.0001) were willing and able to dispense a 1-week supply of generic BUP/NX and a single unit of NNS. BUP/NX alone was available in 42.2% of pharmacies (52.4% of chains versus 21.5% of independents, P < 0.0001). NNS alone was available in 60.1% of pharmacies (77.9% of chains versus 24.0% of independents, P < 0.0001). Of the 397 pharmacies with generic BUP/NX unavailable, 62.2% of pharmacies (73.9% of chains versus 48.0% of independents, P < 0.0001) indicated willingness to order.
CONCLUSIONS
Most pharmacies in Texas do not appear to be willing and able to dispense prescribed buprenorphine/naloxone films and naloxone nasal spray to patients with opioid use disorder in a timely manner. Deficiencies in availability are markedly more pronounced in independent pharmacies compared with chain pharmacies.
Substances chimiques
Narcotic Antagonists
0
Nasal Sprays
0
Naloxone
36B82AMQ7N
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1505-1511Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Society for the Study of Addiction.
Références
Larochelle M. R., Bernson D., Land T., Stopka T. J., Wang N., Xuan Z. et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med 2018; 169: 137-145.
Sordo L., Barrio G., Bravo M. J., Indave B. I., Degenhardt L., Wiessing L. et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017; 357: j1550.
Davis C. S., Carr D. H. Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States. Int J Drug Policy 2019; 73: 42-48.
Fiscella K., Wakeman S. E., Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver. JAMA Psychiat 2019; 76: 229-230.
Thomas C. P., Doyle E., Kreiner P. W., Jones C. M., Dubenitz J., Horan A. et al. Prescribing patterns of buprenorphine waivered physicians. Drug Alcohol Depend 2017; 181: 213-218.
Jones C. M., McCance-Katz E. F. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction 2019; 114: 471-482.
Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality; 2019.
Kilaru A. S., Xiong A., Lowenstein M., Meisel Z. F., Perrone J., Khatri U. et al. Incidence of treatment for opioid use disorder following nonfatal overdose in commercially insured patients. JAMA Netw Open 2020; 3: e205852.
Cataife G., Dong J., Davis C. S. Regional and temporal effects of naloxone access laws on opioid overdose mortality. Subst Abuse 2020. https://doi.org/10.1080/08897077.2019.1709605
Roberts A. W., Carpenter D. M., Smith A., Look K. A. Reviewing state-mandated training requirements for naloxone-dispensing pharmacists. Res Social Adm Pharm 2019; 15: 222-225.
Graves R. L., Andreyeva E., Perrone J., Shofer F. S., Merchant R. M., Meisel Z. F. Naloxone availability and pharmacy staff knowledge of standing order for naloxone in Pennsylvania pharmacies. J Addict Med 2019; 13: 272-278.
Stopka T. J., Donahue A., Hutcheson M., Green T. C. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015. J Am Pharm Assoc 2017; 57: S34-S44.
Meyerson B. E., Agley J. D., Davis A., Jayawardene W., Hoss A., Shannon D. J. et al. Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016. Drug Alcohol Depend 2018; 188: 187-192.
Evoy K. E., Hill L. G., Groff L., Mazin L., Carlson C. C., Reveles K. R. Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas. JAMA 2018; 320: 1934-1937.
Puzantian T., Gasper J. J. Provision of naloxone without a prescription by California pharmacists 2 years after legislation implementation. JAMA 2018; 320: 1933-1934.
Eldridge L. A., Agley J., Meyerson B. E. Naloxone availability and dispensing in Indiana pharmacies 2 years after the implementation of a statewide standing order. J Am Pharm Assoc 2020; 60: 470-474.
Guadamuz J. S., Alexander G. C., Chaudhri T., Trotzky-Sirr R., Qato D. M. Availability and cost of naloxone nasal spray at pharmacies in Philadelphia, Pennsylvania, 2017. JAMA Netw Open 2019; 2: e195388.
Thakur T., Frey M., Chewning B. Pharmacist roles, training, and perceived barriers in naloxone dispensing: a systematic review. J Am Pharm Assoc 2020; 60: 178-194.
Muzyk A., Smothers Z. P. W., Collins K., MacEachern M., Wu L. T. Pharmacists’ attitudes toward dispensing naloxone and medications for opioid use disorder: a scoping review of the literature. Subst Abuse 2019; 40: 476-483.
Thornton J. D., Lyvers E., Scott V. G. G., Dwibedi N. Pharmacists’ readiness to provide naloxone in community pharmacies in West Virginia. J Am Pharm Assoc 2017; 57: S12-S8 e4; https://doi.org/10.1016/j.drugpo.2020.102701
Ventricelli D. J., Mathis S. M., Foster K. N., Pack R. P., Tudiver F., Hagemeier N. E. Communication experiences of DATA-waivered physicians with community pharmacists: a qualitative study. Subst Use Misuse 2020; 55: 349-357.
Cooper H. L., Cloud D. H., Young A. M., Freeman P. R. When prescribing isn't enough-pharmacy-level barriers to buprenorphine access. N Engl J Med 2020; 383: 703-705.
Joudrey P. J., Khan M. R., Wang E. A., Scheidell J. D., Edelman E. J., McInnes D. K. et al. A conceptual model for understanding post-release opioid-related overdose risk. Addict Sci Clin Pract 2019; 14: 17.
Weiner S. G., Baker O., Bernson D., Schuur J. D. One-year mortality of patients after emergency department treatment for nonfatal opioid overdose. Ann Emerg Med 2020; 75: 13-17.
Ranapurwala S. I., Shanahan M. E., Alexandridis A. A., Proescholdbell S. K., Naumann R. B., Edwards D. J. et al. Opioid overdose mortality among former North Carolina inmates: 2000-2015. Am J Public Health 2018; 108: 1207-1213.
Strang J., McCambridge J., Best D., Beswick T., Bearn J., Rees S. et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003; 326: 959-960.
US Census Bureau. Metropolitan and micropolitan statistical area reference files [updated March 2020]. Available at: https://www.census.gov/geographies/reference-files/time-series/demo/metro-micro/delineation-files.html (accessed 16 November 2020).
Saloner B., Levin J., Chang H. Y., Jones C., Alexander G. C. Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the affordable care act Medicaid expansion. JAMA Netw Open 2018; 1: e181588.
Wen H., Druss B. G., Cummings J. R. Effect of Medicaid expansions on health insurance coverage and access to care among low-income adults with behavioral health conditions. Health Serv Res 2015; 50: 1787-1809.
Orgera K., Tolbert J. The opioid epidemic and Medicaid's role in facilitating access to treatment: Kaiser Family Foundation; May 2019. Available at: https://www.kff.org/medicaid/issue-brief/the-opioid-epidemic-and-medicaids-role-in-facilitating-access-to-treatment/ (accessed 16 November 2020).
Gertner A. K., Robertson A. G., Jones H., Powell B. J., Silberman P., Domino M. E. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints. Health Serv Res 2020; 55: 383-392.
Roehler D. R., Guy G. P. Jr., Jones C. M. Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: a cross-sectional study. Drug Alcohol Depend 2020; 213: 108083.